Roche’s Alecensa approved in Europe, with head-to-head data coming
Alecensa part of Roche’s goal of becoming dominant player in NSCLC
X
Roche’s Alecensa approved in Europe, with head-to-head data coming
https://pharmaphorum.com/news/alecensa/
NSCLC
Merck soars on Keytruda combination filing
Approval by May could put Keytruda in pole position
Can Keytruda beat Opdivo to full UK access in lung cancer?
A decisive moment in lung cancer treatment is nearing
BMS and Nektar to pair Opdivo with natural killer cell drug
BMS and Nektar’s combination latest in frenzied immunotherapy field
Merck makes its move: Keytruda filed for first line lung cancer
Merck steals a march on rival BMS.
BMS’ Opdivo stumbles in lung cancer, but could still maintain lead
Analysts expect Opdivo to recover via combination trials
New data supports key AZ cancer drug
Tagrisso could help revive sales after patent losses.
Scotland’s Opdivo decision sparks funding row
Patients in Scotland will receive lung cancer drug, those in England will not.